Patrick Taylor Horn
Chief Tech/Sci/R&D Officer bij FULCRUM THERAPEUTICS, INC.
Profiel
Patrick Taylor Horn is currently the Chief Medical Officer at Fulcrum Therapeutics, Inc. He previously held positions as the Medical Director & Head-Clinical Pharmacology at Abbott Laboratories from 2001 to 2006, Vice President-Clinical & Medical Affairs at Dyax Corp.
from 2007 to 2010, Chief Medical Officer at Tetraphase Pharmaceuticals, Inc. from 2011 to 2017, Senior VP-Medical & Clinical Development at Orphan Technologies Ltd.
in 2018, and Chief Medical Officer at Albireo Pharma, Inc. from 2018 to 2021.
He is also currently the Chief Medical Officer at HemoShear Therapeutics, Inc. Dr. Horn obtained a doctorate degree from The University of Chicago and Pritzker School of Medicine, and an undergraduate degree from the University of Illinois.
Actieve functies van Patrick Taylor Horn
Bedrijven | Functie | Begin |
---|---|---|
FULCRUM THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 18-03-2024 |
Eerdere bekende functies van Patrick Taylor Horn
Bedrijven | Functie | Einde |
---|---|---|
ALBIREO PHARMA, INC. | Chief Tech/Sci/R&D Officer | 31-12-2021 |
Orphan Technologies Ltd.
Orphan Technologies Ltd. Pharmaceuticals: MajorHealth Technology Orphan Technologies Ltd. engages in the manufacturing of biopharmaceutical drugs. It develops novel therapies for patients suffering from rare disorder and classical homocystinuria. The company is headquartered in Rapperswil, Switzerland. | Corporate Officer/Principal | 01-07-2018 |
TETRAPHASE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 29-12-2017 |
DYAX CORP. | Chief Tech/Sci/R&D Officer | 01-12-2010 |
ABBOTT LABORATORIES | Chief Tech/Sci/R&D Officer | 01-01-2006 |
Opleiding van Patrick Taylor Horn
The University of Chicago | Doctorate Degree |
University of Illinois | Undergraduate Degree |
Pritzker School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ABBOTT LABORATORIES | Health Technology |
FULCRUM THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Dyax Corp.
Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
HemoShear Therapeutics, Inc.
HemoShear Therapeutics, Inc. Medical/Nursing ServicesHealth Services HemoShear Therapeutics LLC engages in the development of human-relevant systems for applications in drug research and development. It creates human relevant systems that replicate the biology of organ systems and diseases throughout drug discovery and development. The firm's technology imposes human-derived hemodynamic forces on human primary cells to recreate human biology. The company was founded by Brian R. Wamhoff and Brett R. Blackman in 2008 and is headquartered in Charlottesville, VA. | Health Services |
Orphan Technologies Ltd.
Orphan Technologies Ltd. Pharmaceuticals: MajorHealth Technology Orphan Technologies Ltd. engages in the manufacturing of biopharmaceutical drugs. It develops novel therapies for patients suffering from rare disorder and classical homocystinuria. The company is headquartered in Rapperswil, Switzerland. | Health Technology |
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |